Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Malignant Melanoma

  Free Subscription


22.01.2018

2 Ann Surg Oncol
1 Cancer Lett
1 Clin Cancer Res
1 Eur J Dermatol
1 J Am Acad Dermatol
1 J Clin Oncol
3 J Immunother
2 JAMA
1 Melanoma Res
1 Nat Med
1 Ophthalmology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. TRINH BB, Chapman BC, Gleisner A, Kwak JJ, et al
    SPECT/CT Adds Distinct Lymph Node Basins and Influences Radiologic Findings and Surgical Approach for Sentinel Lymph Node Biopsy in Head and Neck Melanoma.
    Ann Surg Oncol. 2018 Jan 12. pii: 10.1245/s10434-017-6298.
    PubMed     Text format     Abstract available

  2. LO SN, Scolyer RA, Thompson JF
    Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors.
    Ann Surg Oncol. 2018 Jan 12. pii: 10.1245/s10434-017-6325.
    PubMed     Text format     Abstract available


    Cancer Lett

  3. MIRZAEI H, Salehi H, Oskuee RK, Mohammadpour A, et al
    The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30051.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  4. WINKLER F, Osswald M, Blaes J, Liao Y, et al
    Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1327.2016.
    PubMed     Text format     Abstract available


    Eur J Dermatol

  5. FINON A, Zaragoza J, Maillard H, Beneton N, et al
    A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma.
    Eur J Dermatol. 2018 Jan 16. pii: ejd.2017.3167. doi: 10.1684/ejd.2017.3167.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  6. DEUTSCH GB, Tyrell R, Yost S, Deutsch MB, et al
    Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy.
    J Am Acad Dermatol. 2018;78:419-421.
    PubMed     Text format    


    J Clin Oncol

  7. HORIGUCHI M, Uno H, Wei LJ
    Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.
    J Clin Oncol. 2018 Jan 16:JCO2017760983. doi: 10.1200/JCO.2017.76.0983.
    PubMed     Text format    


    J Immunother

  8. YU G, Moudgil T, Cui Z, Mou Y, et al
    Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
    J Immunother. 2017;40:155-163.
    PubMed     Text format     Abstract available

  9. KELLY WU W, Broman KK, Brownie ER, Kauffmann RM, et al
    Ipilimumab-induced Guillain-Barre Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
    J Immunother. 2017;40:196-199.
    PubMed     Text format     Abstract available

  10. GORDY JT, Luo K, Francica B, Drake C, et al
    Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3alpha-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.
    J Immunother. 2018 Jan 12. doi: 10.1097/CJI.0000000000000212.
    PubMed     Text format     Abstract available


    JAMA

  11. LIU W, Liu JW, Ma DL
    Dermoscopic Patterns of Spitz Nevi-Reply.
    JAMA. 2018;319:194.
    PubMed     Text format    

  12. POLLOCK JL
    Dermoscopic Patterns of Spitz Nevi.
    JAMA. 2018;319:194.
    PubMed     Text format    


    Melanoma Res

  13. ROSE AM, Radia UK, Luo R, Kalirai H, et al
    Multiple primary malignancies and prolonged survival in a patient with widespread metastatic cutaneous melanoma.
    Melanoma Res. 2018 Jan 17. doi: 10.1097/CMR.0000000000000426.
    PubMed     Text format    


    Nat Med

  14. BOSHUIZEN J, Koopman LA, Krijgsman O, Shahrabi A, et al
    Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
    Nat Med. 2018 Jan 15. pii: nm.4472. doi: 10.1038/nm.4472.
    PubMed     Text format     Abstract available


    Ophthalmology

  15. SHIELDS CL, Di Nicola M, Bekerman VP, Kaliki S, et al
    Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.
    Ophthalmology. 2018 Jan 13. pii: S0161-6420(17)32069.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: